Polymorphisms in ERCC1 gene affect mRNA expression and have received much attention as potential predictors of cisplatin and platinum adjuvant therapy outcome, and patient prognosis in lung cancer [14]–[16], melanoma [17], bladder cancer [18], [19], in addition to esophageal cancer [1], [20]–[23]. This evidence concerns the gene ERCC1 and urinary bladder cancer.